SpringerLink
Log in

Translational Research in Lung Cancer

  • Chapter
  • First Online:
Advances in Radiation Oncology in Lung Cancer

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 408 Accesses

Abstract

For decades, the National Institutes of Health (NIH) has been funding basic biomedical research that aims to understand how living organisms work until the NIH Roadmap initiative (Fig. 1), with increased focus on the need to “translate” basic research more quickly into human studies and then into tests and treatments that can improve clinical practices for the benefit of patients (Westfall et al. 2007). Since then, translational research for lung cancer has undergone evolution with tremendous progress in discovering new molecular markers of lung cancer, some of which provide the prognosis of tumors expressing such markers, while others predict the treatment response to specific molecular targeted therapy toward tumor-specific mutations and toward immunotherapy. The predictive marker discoveries have changed the landscape of lung cancer treatment into progressively more personalized medicine. We summarize the progress in translational investigations of molecular markers of lung cancer with an emphasis on non-small cell lung cancer (NSCLC) and present examples of clinical trials that are built on information from translational investigations in the laboratory.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (Brazil)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (Brazil)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (Brazil)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aggarwal C (2016) Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024. Ann Oncol 27:VVI363

    Google Scholar 

  • Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919–1929

    Google Scholar 

  • Antonia SJ, Villegas A, Daniel D et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 379:2342–2350

    Google Scholar 

  • Arnold KM, Flynn NJ, Raben A et al (2018) The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules. Cancer Growth Metastasis 11:1–17

    Google Scholar 

  • Arriagada R, le Chevalier T, Quoix E et al (1991) ASTRO plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys 20:1183–1190

    Google Scholar 

  • Arriagada R, Bergman B, Dunant A et al (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360

    Google Scholar 

  • Arteaga CL (2003) ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284:122–130

    Google Scholar 

  • Barbacid M (1987) Ras genes. Annu Rev Biochem 56:779–827

    Google Scholar 

  • Bepler G, Sommers KE, Cantor A et al (2008) Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 3:1112–1118

    Google Scholar 

  • Bepler G, Olaussen KA, Vataire AL et al (2011) ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol 178:69–78

    Google Scholar 

  • Berger MS, Gullick WJ, Greenfield C et al (1987) Epidermal growth factor receptors in lung tumours. J Pathol 152:297–307

    Google Scholar 

  • Bhattacharjee A, Richards WG, Staunton J et al (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98:13790–13795

    Google Scholar 

  • Booton R, Ward T, Ashcroft L et al (2007) ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2:902–906

    Google Scholar 

  • Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49:4682–4689

    Google Scholar 

  • Boutros T, Chevet E, Metrakos P (2008) Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev 60:261–310

    Google Scholar 

  • Bradley JD, Paulus R, Komaki R et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomized, two-by-two factorial phase 3 study. Lancet Oncol 16:187–199

    Google Scholar 

  • Brose MS, Volpe P, Feldman M et al (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997–7000

    Google Scholar 

  • Brustugun OT, Khattak AM, Tromborg AK et al (2014) BRAF-mutations in non-small cell lung cancer. Lung Cancer 84:36–38

    Google Scholar 

  • Ceppi P, Volante M, Novello S et al (2006) ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17:1818–1825

    Google Scholar 

  • Chen Y, Gandara D (2006) Molecular staging of non-small cell lung cancer. In: Syrigos KN, Nutting C, Roussos C (eds) Tumors of the chest: biology diagnosis and management. Springer, pp 159–176

    Google Scholar 

  • Chen Y, Okunieff P (2004) Radiation and third generation chemotherapy. Hematol Oncol Clin N Am 18:55–80

    Google Scholar 

  • Chen P, Wiencke J, Aldape K et al (1998) Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 9:843–847

    Google Scholar 

  • Chen Y, Pandya K, Keng P et al (2001) Schedule dependent pulsed low-dose paclitaxel radiosensitization for thoracic malignancy. Am J Clin Oncol 24:432–437

    Google Scholar 

  • Chen Y, Pandya K, Keng PC et al (2003) Phase I/II clinical trial using pulsed low-dose paclitaxel radiosensitization for thoracic malignancies: a therapeutic approach based on pre-clinical research of human lung cancer cells. Clin Cancer Res 9:969–975

    Google Scholar 

  • Chen HY, Yu SL, Chen CH et al (2007) A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356:11–20

    Google Scholar 

  • Chen Y, Pandya K, Feins R et al (2008) Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 71:407–413

    Google Scholar 

  • Chen Y, Pandya KJ, Hyrien O et al (2011) Preclinical and pilot clinical study of docetaxel chemoradiation for stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 80:1358–1364

    Google Scholar 

  • Chen D, Zhang LQ, Huang JF et al (2014) BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 9:e10135

    Google Scholar 

  • Cobo M, Isla D, Massuti B et al (2007) Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25:2747–2754

    Google Scholar 

  • Cooper WA, Kohonen-Corish MR, Chan C et al (2008) Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions. Histopathology 52:613–622

    Google Scholar 

  • Cordon-Cardo C (1995) Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147:545–560

    Google Scholar 

  • Cox G, Jones JL, O'Byrne KJ (2000) Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 6:2349–2355

    Google Scholar 

  • Curran WJ, Paulus R, Langer CJ et al (2011) Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:1452–1460

    Google Scholar 

  • D’Amico TA, Massey M, Herndon JE 2nd et al (1999) A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117:736–743

    Google Scholar 

  • Dagogo-Jack I, Martinez P, Yeap BY et al (2018) Impact of BRAF mutation class on disease characteristics and clinical outcomes in BRAF-mutant lung cancer. Clin Cancer Res 25:158–165

    Google Scholar 

  • Demaria S, Formenti SC (2020) The abscopal effect 67 years later: from a side tory to center stage. Br J Radiol 93:20200042

    Google Scholar 

  • Deng L, Liang H, Burnette B et al (2014a) Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124:687–695

    Google Scholar 

  • Deng L, Liang H, Xu M et al (2014b) STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41:843–852

    Google Scholar 

  • Dewan MZ, Galloway AE, Kawashima N et al (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15:5379–5388

    Google Scholar 

  • Dovedi SJ, Cheadle EJ, Popple AL et al (2017) Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-Cell populations when combined with PD-1 blockade. Clin Cancer Res 23:5514–5526

    Google Scholar 

  • Drilon A, Wang L, Hasanovic A et al (2013) Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 3:630–635

    Google Scholar 

  • Drilon A, Lin JJ, Filleron T et al (2018) Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers. J Thorac Oncol 13:1595–1601

    Google Scholar 

  • Drilon A, Oxnard GR, Tan DSW et al (2020) Efficacy of selpercatinib in RET fusion-positive non-small cell lung cancer. N Engl J Med 383:813–824

    Google Scholar 

  • Faivre-Finn C, Vicente D, Kurata T et al (2021) Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC—an update from the PACIFIC trial. J Thorac Oncol 16(5):860–867

    Google Scholar 

  • Farmer G, Bargonetti J, Zhu H et al (1992) Wild-type p53 activates transcription in vitro. Nature 358:83–86

    Google Scholar 

  • Feng Y, Thiagarajan PS, Ma PC (2012) MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol 7:459–467

    Google Scholar 

  • Fontanini G, De Laurentiis M, Vignati S et al (1998) Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 4:241–249

    Google Scholar 

  • Formenti SC, Demaria S (2009) Systemic effects of local radiotherapy. Lancet Oncol 10:718–726

    Google Scholar 

  • Franklin WA, Veve R, Hirsch FR et al (2002) Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 29(1 Suppl 4):3–14

    Google Scholar 

  • Fujii T, Toyooka S, Ichimura K et al (2008) ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 59:377–384

    Google Scholar 

  • Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237–2246

    Google Scholar 

  • Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692

    Google Scholar 

  • Gandara DR, Valone FH, Perez EA et al (1991) Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer. results of a Phase I/II study. Int J Radiat Oncol Biol Phys 20:1047–1052

    Google Scholar 

  • Gandhi L, Rodriguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092

    Google Scholar 

  • Gautam A, Bepler G (2006) Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res 66:6497–6502

    Google Scholar 

  • Gazdar AF (2007) DNA repair and survival in lung cancer—the two faces of Janus. N Engl J Med 356:771–773

    Google Scholar 

  • Golden EB, Frances D, Pellicciotta I et al (2014) Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 3:e28518

    Google Scholar 

  • Golden EB, Marciscano AE, Formenti SC (2020) Radiation therapy and the in situ vaccination approach. Int J Radiat Oncol Biol Phys 108:891–898

    Google Scholar 

  • Greatens TM, Niehans GA, Rubins JB et al (1998) Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med 157:1093–1097

    Google Scholar 

  • Greenblatt MS, Bennett WP, Hollstein M et al (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878

    Google Scholar 

  • Guo NL, Wan YW, Tosun K et al (2008) Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res 14:8213–8220

    Google Scholar 

  • Han SW, Kim TY, Hwang PG et al (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493–2501

    Google Scholar 

  • Han JY, Park K, Kim SW et al (2012) First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30:1122–1128

    Google Scholar 

  • Hanna NH, Schneider BJ, Temin S et al (2020) Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol 38:1608–1632

    Google Scholar 

  • Haratake N, Seto T (2020) NTRK fusion-positive non-small-cell lung cancer: the diagnosis and targeted therapy. Clin Lung Cancer 22:1–5

    Google Scholar 

  • Hartwell L (1992) Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543–546

    Google Scholar 

  • Herbst RS, Giaccone G, de Marinis F et al (2020) Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med 383:1328–1339

    Google Scholar 

  • Hirsch FR, Varella-Garcia M, Bunn PA Jr et al (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798–3807

    Google Scholar 

  • Hsu HS, Lee IH, Hsu WH et al (2007) Polymorphism in the hMSH2 gene (gISV12-6T > C) is a prognostic factor in non-small cell lung cancer. Lung Cancer 58:123–130

    Google Scholar 

  • Huncharek M, Kupelnick B, Geschwind JF et al (2000) Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer Lett 153:219–226

    Google Scholar 

  • Hwang IG, Ahn MJ, Park BB et al (2008) ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 113:1379–1386

    Google Scholar 

  • Inamura K, Takeuchi K, Togashi Y et al (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22:508–515

    Google Scholar 

  • Janne PA, Engelman JA, Johnson BE (2005) Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23:3227–3234

    Google Scholar 

  • Janne PA, Shaw AT, Pereira JR et al (2013) Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomized, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14:38–47

    Google Scholar 

  • Jorissen RN, Walker F, Pouliot N et al (2003) Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 284:31–53

    Google Scholar 

  • Jung CY, Choi JE, Park JM et al (2006) Polymorphisms in the hMSH2 gene and the risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 15:762–768

    Google Scholar 

  • Kamal NS, Soria JC, Mendiboure J et al (2010) MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 16:1206–1215

    Google Scholar 

  • Khotskaya YB, Holla VR, Farago AF et al (2017) Targeting TRK family proteins in cancer. Pharmacol Ther 173:58–66

    Google Scholar 

  • Kim M, Kang HG, Lee SY et al (2010) Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer. Cancer Sci 101:2436–2442

    Google Scholar 

  • Ko EC, Raben D, Formenti SC (2018) The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer. Clin Cancer Res 24:5792–5806

    Google Scholar 

  • Kohno T, Yokota J (1999) How many tumor suppressor genes are involved in human lung carcinogenesis? Carcinogenesis 20:1403

    Google Scholar 

  • Kordbacheh T, Honeychurch J, Blackhall F et al (2018) Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. Ann Oncol 29:301–310

    Google Scholar 

  • Kosaka T, Yatabe Y, Endoh H et al (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64:8919–8923

    Google Scholar 

  • Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158

    Google Scholar 

  • Kumar A, Petri ET, Halmos B et al (2008) Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 26:1742–1751

    Google Scholar 

  • Larsen JE, Pavey SJ, Bowman R et al (2007) Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement. Eur Respir J 30:21–25

    Google Scholar 

  • Lau SK, Boutros PC, Pintilie M et al (2007) Three-gene prognostic classifier for early-stage non-small-cell lung cancer. J Clin Oncol 25:5562–5569

    Google Scholar 

  • Li J, Li ZN, Yu LC et al (2010) Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer 69:116–122

    Google Scholar 

  • Liao BC, Lin CC, Yang JC (2015) Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol 27:94–101

    Google Scholar 

  • Lin H, Chen Y, Shi A et al (2016) Phase 3 randomized low-dose paclitaxel chemoradiotherapy study for locally advanced non-small cell lung cancer. Front Oncol 6:1–7

    Google Scholar 

  • Lo YL, Hsiao CF, Jou YS et al (2011) Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers. Lung Cancer 72:280–286

    Google Scholar 

  • Lord RV, Brabender J, Gandara D et al (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286–2291

    Google Scholar 

  • Lu Y, Lemon W, Liu PY et al (2006) A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 3:e467

    Google Scholar 

  • Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388

    Google Scholar 

  • Marino P, Preatoni A, Cantoni A (1995) Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer. A meta-analysis. Cancer 76:593–601

    Google Scholar 

  • Mascaux C, Iannino N, Martin B et al (2005) The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92:131–139

    Google Scholar 

  • Mattson K, Holsti LR, Holsti P et al (1988) Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 24:477–482

    Google Scholar 

  • Mayne ST, Buenconsejo J, Janerich DT et al (1999) Familial cancer history and lung cancer risk in USA non-smoking men and women. Cancer Epidemiol Biomarkers Prev 8:1065

    Google Scholar 

  • Mitsudomi T, Steinberg SM, Oie HK et al (1991) Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51:4999–5002

    Google Scholar 

  • Mitsudomi T, Hamajima N, Ogawa M et al (2000) Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6:4055–4063

    Google Scholar 

  • Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 11:121–128

    Google Scholar 

  • Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957

    Google Scholar 

  • Morris SW, Kirstein MN, Valentine MB et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263:1281–1284

    Google Scholar 

  • Morton RF, Jett JR, McGinnis WL et al (1991) Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. Ann Intern Med 115:681–686

    Google Scholar 

  • Ngwa W, Irabor OC, Schoenfeld JD et al (2018) Using immunotherapy to boost the abscopal effect. Nat Rev Cancer 18:313–322

    Google Scholar 

  • Obeid M, Tesniere A, Ghiringhelli F et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54–61

    Google Scholar 

  • Ohsaki Y, Tanno S, Fujita Y et al (2000) Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 7:603–607

    Google Scholar 

  • Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991

    Google Scholar 

  • Paik PK, Arcila ME, Fara M et al (2011) Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29:2046–2051

    Google Scholar 

  • Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73

    Google Scholar 

  • Park S, Ahn B-C, Lim SW et al (2018) Characteristics and outcome of ROS1-positive non-small cell lung cancer patients in routine clinical practiced. J Thorac Oncol 123:1373–1382

    Google Scholar 

  • Pastorino U, Andreola S, Tagliabue E et al (1997) Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15:2858–2865

    Google Scholar 

  • Patsoukis N, Wang Q, Strauss L et al (2020) Revisiting the PD-1 pathway. Sci Adv 6:eabd2712

    Google Scholar 

  • Paz-Ares L, Luft A, Vicente D et al (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379:2040–2051

    Google Scholar 

  • Pfeiffer P, Clausen PP, Andersen K et al (1996) Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 74:86–91

    Google Scholar 

  • Planchard D, Kim TM, Maxieres J et al (2016) Dabrafenib in patients with BRAF (V600E)-positive advanced non-small cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol 17:642–650

    Google Scholar 

  • Pollmann M, Parwaresch R, Adam-Klages S et al (2006) Human EML4, a novel member of the EMAP family, is essential for microtubule formation. Exp Cell Res 312:3241–3251

    Google Scholar 

  • Potti A, Mukherjee S, Petersen R et al (2006) A genomic strategy to refine prognosis in early-stage non-small cell lung cancer. N Engl J Med 355:570–580

    Google Scholar 

  • Potti A, Mukherjee S, Petersen R et al (2011) Retraction: a genomic strategy to refine prognosis in early-stage non-small cell lung cancer. N Engl J Med 364:1176

    Google Scholar 

  • Ramalingham SS, Owonikoko TK, Khuri FR (2011) Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 61:91–112

    Google Scholar 

  • Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833

    Google Scholar 

  • Reed E (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24:331–344

    Google Scholar 

  • Reits EA, Hodge JW, Herberts CA et al (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203:1259–1271

    Google Scholar 

  • Riely GJ, Marks J, Pao W (2009) KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6:201–205

    Google Scholar 

  • Rodenhuis S, Slebos RJ (1992) Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52:2665s–2669s

    Google Scholar 

  • Rodriguez-Ruiz ME, Rodriguez I, Leaman O et al (2019) Immune mechanisms mediating abscopal effects in radioimmunotherapy. Pharmacol Ther 196:195–203

    Google Scholar 

  • Rosell R, Danenberg KD, Alberola V et al (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10:1318–1325

    Google Scholar 

  • Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246

    Google Scholar 

  • Rusch V, Klimstra D, Venkatraman E et al (1997) Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3:515–522

    Google Scholar 

  • Sadiq AA, Salgia R (2013) MET as a possible target for non-small cell lung cancer. J Clin Oncol 31:1089–1096

    Google Scholar 

  • Sause W, Kolesar P, Taylor S IV et al (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest 117:358–364

    Google Scholar 

  • Scartozzi M, Franciosi V, Campanini N et al (2006) Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. Lung Cancer 53:103–109

    Google Scholar 

  • Schaake-Koning C, van den Bogaert W, Dalesio O et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326:524–530

    Google Scholar 

  • Schiller JH, Adak S, Feins RH et al (2001) Lack of prognostic significance of p53 and K-RAS mutations in primary resected non- small-cell lung cancer on e4592: a laboratory ancillary study on an eastern cooperative oncology group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol 19:448–457

    Google Scholar 

  • Sequist LV, Yang JC, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327–3334

    Google Scholar 

  • Sharma SV, Bell DW, Settleman J et al (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169–181

    Google Scholar 

  • Sharpe AH, Pauken KE (2018) The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18:153–167

    Google Scholar 

  • Shaw AT, Yeap BY, Mino-Kenudson M et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247–4253

    Google Scholar 

  • Shaw AT, Kim DW, Nakagawa K et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394

    Google Scholar 

  • Shaw AT, Ou SH, Bang YJ et al (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963–1971

    Google Scholar 

  • Shen MJ, Xu LJ, Yang L et al (2017) Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway. Oncotarget 8:80506–80529

    Google Scholar 

  • Shigematsu H, Lin L, Takahashi T et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339–346

    Google Scholar 

  • Shih CM, Chen CY, Lee IH et al (2010) A polymorphism in the hMLH1 gene (-93G-->A) associated with lung cancer susceptibility and prognosis. Int J Mol Med 25:165–170

    Google Scholar 

  • Simon G, Sharma A, Li X et al (2007) Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 25:2741–2746

    Google Scholar 

  • Sinclair WK, Morton RA (1966) X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29:450–474

    Google Scholar 

  • Skarda J, Fridman E, Pevova P et al (2006) Prognostic value of hMLH1 and hMSH2 immunohistochemical expression in non-small cell lung cancer. A tissue microarray study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 150:255–259

    Google Scholar 

  • Slebos RJ, Kibbelaar RE, Dalesio O et al (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561–565

    Google Scholar 

  • Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378:2288–2301

    Google Scholar 

  • Solomon BJ, Mok T, Kim DW et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177

    Google Scholar 

  • Solomon BJ, Kim DW, Wu YL et al (2018) Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol 36:2251–2258

    Google Scholar 

  • Souglakos J, Boukovinas I, Taron M et al (2008) Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 98:1710–1715

    Google Scholar 

  • Steels E, Paesmans M, Berghmans T et al (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18:705–719

    Google Scholar 

  • Suda K, Bunn PA, Rivard CJ et al (2017) Primary double-strike therapy for cancers to overcome EGFR kinase inhibitor resistance: proposal from the Bench. J Thorac Oncol 12:27–35

    Google Scholar 

  • Sugio K, Ishida T, Yokoyama H et al (1992) Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52:2903–2906

    Google Scholar 

  • Sun Z, Wigle DA, Yang P (2008) Non-overlap** and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol 26:877–883

    Google Scholar 

  • Takeuchi K, Soda M, Togashi Y et al (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378–381

    Google Scholar 

  • Theelen WSME, Peulen HMU, Lalezari F et al (2019) Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol 5:1276–1282

    Google Scholar 

  • Theelen WS, de Jong MC, Baas P (2020) Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: the potential of the abscopal effect. Lung Cancer 142:106–113

    Google Scholar 

  • Vaishnavi A, Capelletti M, Le AT et al (2013) Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 19:1469–1472

    Google Scholar 

  • Vashnavi A, Le AT, Doebele RC (2015) TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 5:25–34

    Google Scholar 

  • Volm M, Efferth T, Mattern J (1992) Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations Anticancer Res 12:11–20

    Google Scholar 

  • Westfall JM, Mold J, Fagnan L (2007) Practice-based research-“Blue Highways” on the NIH roadmap. JAMA 297:403–406

    Google Scholar 

  • Woenckhaus M, Stoehr R, Dietmaier W et al (2003) Microsatellite instability at chromosome 8p in non-small cell lung cancer is associated with lymph node metastasis. Int J Oncol 23(5):1357–1363

    Google Scholar 

  • Wu Q, Christensen LA, Legerski RJ et al (2005) Mismatch repair participates in error-free processing of DNA interstrand crosslinks in human cells. EMBO Rep 6:551–557

    Google Scholar 

  • Wu YL, Zhou C, Hu CP et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15:213–222

    Google Scholar 

  • **narianos G, Liloglou T, Prime W et al (2000) hMLH1 and hMSH2 expression correlates with allelic imbalance on chromosome 3p in non-small cell lung carcinomas. Cancer Res 60:4216–4221

    Google Scholar 

  • Yamazaki T, Hannani D, Poirier-Colame V et al (2014) Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ 21:69–78

    Google Scholar 

  • Yang LY, Li L, Jiang H et al (2000) Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 6:773–781

    Google Scholar 

  • Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2:127–137

    Google Scholar 

  • Yin Y, Tainsky MA, Bischoff FZ et al (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937–948

    Google Scholar 

  • Zak KM, Grudnik P, Magiera K et al (2017) Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2. Structure 25:1163–1174

    Google Scholar 

  • Zhang H, Hyrien O, Pandya K et al (2008) Tumor response kinetics after schedule-dependent paclitaxel chemoradiation treatment for inoperable non-small cell lung cancer: a model for low-dose chemotherapy radiosensitization. J Thorac Oncol 3:563–568

    Google Scholar 

  • Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800–808

    Google Scholar 

  • Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735–742

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA

    Haoming Qiu, Michael A. Cummings & Yuhchyau Chen

Authors
  1. Haoming Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael A. Cummings
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuhchyau Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuhchyau Chen .

Editor information

Editors and Affiliations

  1. School of Medicine, University of Kragujevac, Kragujevac, Serbia

    Branislav Jeremić

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Qiu, H., Cummings, M.A., Chen, Y. (2022). Translational Research in Lung Cancer. In: Jeremić, B. (eds) Advances in Radiation Oncology in Lung Cancer. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/174_2022_346

Download citation

  • DOI: https://doi.org/10.1007/174_2022_346

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-34846-4

  • Online ISBN: 978-3-031-34847-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation